• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    ARS Pharmaceuticals, Inc. - Common Stock (NQ: SPRY )

    10.40 +0.08 (+0.78%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 513,092
    Open 10.15
    Bid (Size) 9.780 (1)
    Ask (Size) 10.60 (10)
    Prev. Close 10.32
    Today's Range 10.08 - 10.43
    52wk Range 2.550 - 11.90
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    SPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024
    SPRY stock results show that ARS Pharmaceuticals met analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    +86.38%
    +86.38%
    1 Month
    +26.21%
    +26.21%
    3 Month
    +22.35%
    +22.35%
    6 Month
    +53.62%
    +53.62%
    1 Year
    +41.30%
    +41.30%

    More News

    Read More
    ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Top 5 Health Care Stocks That May Plunge In March
    Via Benzinga
    SPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023
    Via InvestorPlace
    Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024
    Via InvestorPlace
    ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Allergic Reaction Focused ARS Pharmaceuticals' Lead Candidate Shows Efficacy In Skin Disorder
    Via Benzinga
    ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    ARS Pharma Readies Data In Response To FDA's Rejection For Its EpiPen Alternative For Severe Allergic Reactions
    Via Benzinga
    Exposures Product Safety
    ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Big Stocks Moving Higher On Friday: Synaptics Reports Q1 Beat; Joins Lyft, Hologic, Blink Charging
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
    Via ACCESSWIRE
    NASDAQ:SPRY Investor Notice: Investigation over Potential Securities Laws Violations by ARS Pharmaceuticals, Inc.
    Via SBWire
    ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.